December 11, 2006 — The US Food and Drug Administration (FDA) and Baxter Healthcare Corp have warned healthcare professionals regarding the risk for delayed-onset heparin-induced thrombocytopenia (HIT ...
Therapeutic-dose heparin appears to benefit noncritically-ill COVID-19 patients, but it does not reduce deaths or other adverse endpoints compared with usual-care thromboprophylaxis if it’s initiated ...
A team of researchers developed 3 quality improvement measures embedded in electronic health records (EHRs) to improve care delivery in patients with heparin-induced thrombocytopenia. HIT is known as ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has introduced in the United States two new presentations of Heparin Sodium in convenient, ready-to-administer Freeflex ® IV bags.
According to Maximize Market Research, the Global Heparin Market is projected to reach USD 8.7 billion in 2025 and is ...
WASHINGTON, DC—For STEMI patients undergoing PCI, pretreatment with a loading dose of unfractionated heparin at first medical contact improves spontaneous reperfusion of the infarct-related artery ...
Thiotepa-Based High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Recurrent or Progressive CNS Germ Cell Tumors Patients with advanced malignancy (N = 385) were randomly assigned ...
Heparin-induced thrombocytopenia (HIT) is a clinically significant immune-mediated adverse reaction to heparin therapy. It is typified by a reduction in circulating platelets while paradoxically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results